W
WAVEMAN · COMPANY
RXST · Rxsight, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

RXST

RxSight, Inc.
MEDICAL DEVICES · OPHTHALMIC GOODS · CIK 0001111485
FORM 144 · 5☆ WATCH
INSIDER NET · 180D
-$118.0K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
97
13F, latest reported quarter
REVENUE GROWTH
-3.9%
XBRL, annual
NET MARGIN
-29.0%
CONVERSIONS · 180D
5
codes C/M, not in net · $51.6K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$118.0K over 180 days
-$118.0K over 90 days
more than 59% of Medical Devices
CONGRESS
no member of Congress has reported trading it
FUNDS
97 funds added or opened last quarter
more than 57% of Medical Devices
REVENUE
-3.9% year over year
below 79% of Medical Devices
MARGIN
-29.0% net margin
below 65% of Medical Devices
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$118.0K across 4 people in 180 days.
97 funds added or opened positions in the latest 13F quarter, of 153 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -26.7%
-26.7%12M
-47%-15%+18%+50%2025-092025-102025-122026-032026-052026-072026-09 2026-09-02 · Wilterding Mark sold $54.0K2026-09-02 · Kurtz Ronald M MD sold $35.5K2026-09-02 · Goldshleger Ilya sold $14.2K2026-09-02 · Weinberg Eric sold $14.2K2026-09-02 · Goldshleger Ilya filed to sell $14.2K2026-09-02 · Kurtz Ronald M MD filed to sell $35.5K2026-09-02 · Weinberg Eric filed to sell $14.2K2026-09-02 · Wilterding Mark filed to sell $54.0K2026-08-18 · RAYMOND W COHEN filed to sell $75.7K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $118.0K sold by insiders over 180 days, 97 funds added last quarter, $193.7K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
TMOPENROKBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDX
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, RxSight, Inc. insiders sold a net $118.0K of stock across 157 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Kurtz Ronald M MD
Chief Medical Officer
SELL
2026-09-02
5,100.0
$35.5K
Wilterding Mark
Chief Financial Officer
SELL
2026-09-02
7,765.0
$54.0K
Goldshleger Ilya
Chief Operating Officer
SELL
2026-09-02
2,041.0
$14.2K
Weinberg Eric
See remarks
SELL
2026-09-02
2,041.0
$14.2K
Fountain Tamara
Director
SELL
2025-03-12
7,000.0
$180.0K
157 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 152 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
5,790,408.0 sh
$27.9M
MILLENNIUM MANAGEMENT LLC
3,030,287.0 sh
$14.6M
No Street GP LP
2,055,000.0 sh
$9.9M
NOMURA HOLDINGS INC
2,000,060.0 sh
$9.6M
D. E. Shaw & Co., Inc.
1,985,215.0 sh
$9.6M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Goldshleger Ilya
FILED 2026-09-02
$14.2K
Kurtz Ronald M MD
FILED 2026-09-02
$35.5K
Weinberg Eric
FILED 2026-09-02
$14.2K
Wilterding Mark
FILED 2026-09-02
$54.0K
RAYMOND W COHEN
FILED 2026-08-18
$75.7K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
GRANDEUR PEAK GLOBAL CONTRARIAN FUND
$1.3M POSITION · AS OF 2026-04-30
0.9%
GRANDEUR PEAK GLOBAL MICROCAP FUND
$401.5K POSITION · AS OF 2026-04-30
0.9%
Brown Capital Management Small Company Fund
$1.1M POSITION · AS OF 2026-03-31
0.4%
Artisan International Small-Mid Fund
$8.2M POSITION · AS OF 2026-03-31
0.3%
GRANDEUR PEAK GLOBAL OPPORTUNITIES FUND
$1.0M POSITION · AS OF 2026-04-30
0.3%
DWS Global Small Cap Fund
$583.3K POSITION · AS OF 2026-04-30
0.3%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 4 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release
4
Not applicable
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$4.7M
-$2.2M
$2.5M
-7%
-24%
2024
$7.0M
$5.1M
$5.8M
+206%
-24%
2023
$3.1M
$11.8M
$1.8M
+258%
-28%
2022
$1.0M
$1.2M
$649.4K
+13%
-23%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$134.5M$139.9M$89.1M$49.0M
GROSS PROFIT$103.0M$98.9M$53.8M$21.3M
OPERATING INCOME$-48.2M$-36.9M$-50.1M$-63.3M
NET INCOME$-39$-28$-49$-67
EPS (DILUTED)-0.95-0.71-1.41-2.41
OPERATING CASH FLOW$-15.5M$-16.9M$-41.6M$-58.9M
CASH$19.9M$16.7M$9.7M$11.8M
LONG-TERM DEBT——$0$40.2M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →